Punk Ziegel Downgrades Keryx Biopharmaceuticals (KERX) to Accumulate
More News related to KERX
- Keryx Biopharmaceuticals Receives Nasdaq Notification
- Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
- Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
- Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
More News related to Downgrades
- How to Avoid the 2008 Holiday Shopping "Jingle Perils" Presented by ShopNBC
- T-WORKS Launches Board Marker Projector Screen - A New Generation of Board Screen
- Van Nuys Airport's 80th Anniversary Event Honors Life-Saving Medical Flight Crews
- Microsemi Board Supports CEO; Governance Committee Reviewing Academic Credentials
- U.S. Must Own Up to Misdeeds, Says Grawemeyer Religion Winner
Punk Ziegel downgrades Keryx Biopharmaceuticals (Nasdaq: KERX) from Buy to Accumulate.
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of diseases, including diabetes and cancer.
Related Categories
DowngradesStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
